This video explains the detail pharmacology of clofazimine and Rifampin, a potent antileprosy drug.
Leprosy, also known as Hansen’s disease, is a chronic infectious disease caused by Mycobacterium leprae, a microorganism that has a predilection for the skin and nerves.
The disease is clinically characterized by one or more of the three cardinal signs: hypopigmented or erythematous skin patches with definite loss of sensation, thickened peripheral nerves, and acid-fast bacilli detected on skin smears or biopsy material.
M. leprae primarily infects Schwann cells in the peripheral nerves leading to nerve damage and the development of disabilities.
Pharmacology of Clofazimine: Clofazimine exerts a slow bactericidal effect on Mycobacterium leprae (Hansen's bacillus). Clofazimine inhibits mycobacterial growth and binds preferentially to mycobacterial DNA. Clofazimine also exerts antiinflammatory properties in controlling erythema nodosum leprosum reactions.
Mechanism of action of Clofzimine: It bind to mycobacterial DNA leading to disruption of the cell cycle and eventually kills the bacterium. It may also bind to bacterial potassium transporters, thereby inhibiting their function. Lysophospholipids have been found to mediate the activity of this drug.
B. Pharm II sem Pathology: [ Ссылка ]
B. Pharm 6 sem: [ Ссылка ]
you can follow me on social media:
Facebook:[ Ссылка ]
Twitter: [ Ссылка ]
Instagram: [ Ссылка ]
